Time to viral suppression is not related to achievement of SVR12 in HCV GT1-infected patients treated with ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin

Saleh Ali Alqahtani, R. Ozaras, V. Isakov, D. Wyles, P. Ferenci, J. J. Feld, F. Calinas, M. Gschwantler, E. Gane, D. Crawford, I. M. Jacobson, E. O. Dumas, M. King, Mark Sulkowski

Research output: Contribution to journalArticle

Abstract

High rates of sustained virologic response at post-treatment week 12 (SVR12) were achieved in six phase 3 trials of ombitasvir (OBV, an NS5A inhibitor), paritaprevir (an NS3/4A protease inhibitor) co-dosed with ritonavir (PTV/r) + dasabuvir (DSV, an NS5B RNA polymerase inhibitor) (ie, 3D regimen) with or without ribavirin (RBV) in adults with chronic genotype (GT) 1 hepatitis C virus (HCV) infection. We assessed whether time to first HCV RNA value below the lower limit of quantification in patients with and without cirrhosis was associated with achievement of SVR12. Data were analysed from GT1-infected patients enrolled in six phase 3 studies of 3D ± RBV. Patients who experienced non-virologic failure were excluded from analysis. HCV RNA was determined using the Roche COBAS TaqMan RT-PCR assay (lower limit of quantification, LLOQ =25 IU/mL). SVR12 was analysed by week of first HCV RNA suppression, defined as HCV RNA <LLOQ. The analysis included a total of 2027 patients. Cumulative proportions of subjects with initial HCV RNA suppression <LLOQ at weeks 1, 2, 4 and 6 were 31%, 81%, 99% and 100%, respectively. SVR12 was achieved by 98%, 97%, 98% and 92% of patients with initial suppression at Weeks 1, 2, 4 and 6, respectively (P=.42, trend test). Across six phase 3 trials of 3D ± RBV, most patients achieved viral suppression by week 2. Time to viral suppression was not associated with subsequent achievement of SVR12, suggesting that on-treatment virologic monitoring may not be necessary with this regimen.

Original languageEnglish (US)
JournalJournal of Viral Hepatitis
DOIs
StateAccepted/In press - 2016

Fingerprint

Ritonavir
Ribavirin
Hepacivirus
RNA
Virus Diseases
DNA-Directed RNA Polymerases
Protease Inhibitors
ABT-450
ABT-267
ABT-333
Fibrosis
Genotype
Polymerase Chain Reaction
Therapeutics

Keywords

  • Direct-acting antiviral
  • Interferon-free therapy
  • Sustained virologic response

ASJC Scopus subject areas

  • Hepatology
  • Infectious Diseases
  • Virology

Cite this

Time to viral suppression is not related to achievement of SVR12 in HCV GT1-infected patients treated with ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin. / Alqahtani, Saleh Ali; Ozaras, R.; Isakov, V.; Wyles, D.; Ferenci, P.; Feld, J. J.; Calinas, F.; Gschwantler, M.; Gane, E.; Crawford, D.; Jacobson, I. M.; Dumas, E. O.; King, M.; Sulkowski, Mark.

In: Journal of Viral Hepatitis, 2016.

Research output: Contribution to journalArticle

Alqahtani, Saleh Ali ; Ozaras, R. ; Isakov, V. ; Wyles, D. ; Ferenci, P. ; Feld, J. J. ; Calinas, F. ; Gschwantler, M. ; Gane, E. ; Crawford, D. ; Jacobson, I. M. ; Dumas, E. O. ; King, M. ; Sulkowski, Mark. / Time to viral suppression is not related to achievement of SVR12 in HCV GT1-infected patients treated with ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin. In: Journal of Viral Hepatitis. 2016.
@article{60420e48ea6440dfa3f13425ea5f959b,
title = "Time to viral suppression is not related to achievement of SVR12 in HCV GT1-infected patients treated with ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin",
abstract = "High rates of sustained virologic response at post-treatment week 12 (SVR12) were achieved in six phase 3 trials of ombitasvir (OBV, an NS5A inhibitor), paritaprevir (an NS3/4A protease inhibitor) co-dosed with ritonavir (PTV/r) + dasabuvir (DSV, an NS5B RNA polymerase inhibitor) (ie, 3D regimen) with or without ribavirin (RBV) in adults with chronic genotype (GT) 1 hepatitis C virus (HCV) infection. We assessed whether time to first HCV RNA value below the lower limit of quantification in patients with and without cirrhosis was associated with achievement of SVR12. Data were analysed from GT1-infected patients enrolled in six phase 3 studies of 3D ± RBV. Patients who experienced non-virologic failure were excluded from analysis. HCV RNA was determined using the Roche COBAS TaqMan RT-PCR assay (lower limit of quantification, LLOQ =25 IU/mL). SVR12 was analysed by week of first HCV RNA suppression, defined as HCV RNA <LLOQ. The analysis included a total of 2027 patients. Cumulative proportions of subjects with initial HCV RNA suppression <LLOQ at weeks 1, 2, 4 and 6 were 31{\%}, 81{\%}, 99{\%} and 100{\%}, respectively. SVR12 was achieved by 98{\%}, 97{\%}, 98{\%} and 92{\%} of patients with initial suppression at Weeks 1, 2, 4 and 6, respectively (P=.42, trend test). Across six phase 3 trials of 3D ± RBV, most patients achieved viral suppression by week 2. Time to viral suppression was not associated with subsequent achievement of SVR12, suggesting that on-treatment virologic monitoring may not be necessary with this regimen.",
keywords = "Direct-acting antiviral, Interferon-free therapy, Sustained virologic response",
author = "Alqahtani, {Saleh Ali} and R. Ozaras and V. Isakov and D. Wyles and P. Ferenci and Feld, {J. J.} and F. Calinas and M. Gschwantler and E. Gane and D. Crawford and Jacobson, {I. M.} and Dumas, {E. O.} and M. King and Mark Sulkowski",
year = "2016",
doi = "10.1111/jvh.12641",
language = "English (US)",
journal = "Journal of Viral Hepatitis",
issn = "1352-0504",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Time to viral suppression is not related to achievement of SVR12 in HCV GT1-infected patients treated with ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin

AU - Alqahtani, Saleh Ali

AU - Ozaras, R.

AU - Isakov, V.

AU - Wyles, D.

AU - Ferenci, P.

AU - Feld, J. J.

AU - Calinas, F.

AU - Gschwantler, M.

AU - Gane, E.

AU - Crawford, D.

AU - Jacobson, I. M.

AU - Dumas, E. O.

AU - King, M.

AU - Sulkowski, Mark

PY - 2016

Y1 - 2016

N2 - High rates of sustained virologic response at post-treatment week 12 (SVR12) were achieved in six phase 3 trials of ombitasvir (OBV, an NS5A inhibitor), paritaprevir (an NS3/4A protease inhibitor) co-dosed with ritonavir (PTV/r) + dasabuvir (DSV, an NS5B RNA polymerase inhibitor) (ie, 3D regimen) with or without ribavirin (RBV) in adults with chronic genotype (GT) 1 hepatitis C virus (HCV) infection. We assessed whether time to first HCV RNA value below the lower limit of quantification in patients with and without cirrhosis was associated with achievement of SVR12. Data were analysed from GT1-infected patients enrolled in six phase 3 studies of 3D ± RBV. Patients who experienced non-virologic failure were excluded from analysis. HCV RNA was determined using the Roche COBAS TaqMan RT-PCR assay (lower limit of quantification, LLOQ =25 IU/mL). SVR12 was analysed by week of first HCV RNA suppression, defined as HCV RNA <LLOQ. The analysis included a total of 2027 patients. Cumulative proportions of subjects with initial HCV RNA suppression <LLOQ at weeks 1, 2, 4 and 6 were 31%, 81%, 99% and 100%, respectively. SVR12 was achieved by 98%, 97%, 98% and 92% of patients with initial suppression at Weeks 1, 2, 4 and 6, respectively (P=.42, trend test). Across six phase 3 trials of 3D ± RBV, most patients achieved viral suppression by week 2. Time to viral suppression was not associated with subsequent achievement of SVR12, suggesting that on-treatment virologic monitoring may not be necessary with this regimen.

AB - High rates of sustained virologic response at post-treatment week 12 (SVR12) were achieved in six phase 3 trials of ombitasvir (OBV, an NS5A inhibitor), paritaprevir (an NS3/4A protease inhibitor) co-dosed with ritonavir (PTV/r) + dasabuvir (DSV, an NS5B RNA polymerase inhibitor) (ie, 3D regimen) with or without ribavirin (RBV) in adults with chronic genotype (GT) 1 hepatitis C virus (HCV) infection. We assessed whether time to first HCV RNA value below the lower limit of quantification in patients with and without cirrhosis was associated with achievement of SVR12. Data were analysed from GT1-infected patients enrolled in six phase 3 studies of 3D ± RBV. Patients who experienced non-virologic failure were excluded from analysis. HCV RNA was determined using the Roche COBAS TaqMan RT-PCR assay (lower limit of quantification, LLOQ =25 IU/mL). SVR12 was analysed by week of first HCV RNA suppression, defined as HCV RNA <LLOQ. The analysis included a total of 2027 patients. Cumulative proportions of subjects with initial HCV RNA suppression <LLOQ at weeks 1, 2, 4 and 6 were 31%, 81%, 99% and 100%, respectively. SVR12 was achieved by 98%, 97%, 98% and 92% of patients with initial suppression at Weeks 1, 2, 4 and 6, respectively (P=.42, trend test). Across six phase 3 trials of 3D ± RBV, most patients achieved viral suppression by week 2. Time to viral suppression was not associated with subsequent achievement of SVR12, suggesting that on-treatment virologic monitoring may not be necessary with this regimen.

KW - Direct-acting antiviral

KW - Interferon-free therapy

KW - Sustained virologic response

UR - http://www.scopus.com/inward/record.url?scp=85006791156&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85006791156&partnerID=8YFLogxK

U2 - 10.1111/jvh.12641

DO - 10.1111/jvh.12641

M3 - Article

JO - Journal of Viral Hepatitis

JF - Journal of Viral Hepatitis

SN - 1352-0504

ER -